Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Looking for the Best Scientific Minds to Partner With?
Posted on September 7th, 2017 by Christine de Vries - Scheidegger in Pharma R&D
Having access to a robust network of experts provides companies a real leg up in pursuing the most innovative approaches to drug discovery. When exploring unchartered territories such as new therapeutic areas or new molecules, the most competitive companies tap into the best minds in science and have sufficient insights for choosing which experts to collaborate with and which avenues to pursue. This is where comprehensive access to literature and research trends matters.
In a recent case study, an R&D executive at a mid-market pharma company describes how her team’s efforts to move compounds successfully through the pre-clinical phase often requires identifying and leveraging external expertise. They use Scopus the world’s largest citation and abstract database of peer-reviewed literature – for quickly finding and assessing potential experts they can connect with to get help in everything from providing cutting-edge research insights to helping with trial design.
Scopus makes it easy to search the literature and discover who is publishing papers in specific fields and topics. This is not only critical for building relationships with subject matter experts to help with one’s own work, but also for keeping tabs on competitors (and, consequently, staying one step ahead of them).
For the R&D executive featured in this case study, the primary and immediate advantages of Scopus are that it boosts productivity and increases the likelihood of success. Whether it’s cutting down on time spent searching or helping researchers get crucial information that prevents them from wasting time down the line, the savings on the clock and additional insight can end up equaling millions of revenue for the company.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Christine de Vries - Scheidegger
Head of Market Development, Corporate R&D at Elsevier
- AI in Drug Discovery Has Great Potential – But Also Significant Barriers
- Emulating start-up success with purpose-built data tools
- Finding Answers Where You Least Expect Them
- Machine Learning Could Make Drug Discovery Faster, Cheaper, Better
- AI Can Work Wonders, But Can It Create Miracle Cures?